WCH Wacker Chemie AG
Wacker Chemie AG, together with its subsidiaries, produces and sells chemical products in Europe, Asia, the Americas, and internationally. The company operates through four segments: Silicones, Polymers, Biosolutions, and Polysilicon. It offers silanes, siloxanes, silicone fluids, silicone emulsions, silicone elastomers, silicone resins, and pyrogenic silica; and binders and polymeric additives, including dispersible polymer powders and dispersions. The company also provides pharmaceutical proteins, vaccines, cyclodextrins, cysteine, polyvinyl acetate solid resins, and acetylacetone, as well as pharmaceutical actives, food additives, and agrochemicals; and hyperpure polysilicon. In addition, it engages in forums; e-business, such as ERP system, EDI integration, delivery forecast, and e-invoicing; and support services. The company serves automotive, construction, chemical, semiconductor, consumer goods, medical technology, pharmaceutical, and photovoltaic industries. It exports its products. The company was formerly known as Wacker-Chemie GMBH and changed its name to Wacker Chemie AG in October 2005. Wacker Chemie AG was founded in 1914 and is headquartered in Munich, Germany. The company operates as a subsidiary of Dr. Alexander Wacker Familiengesellschaft mbH.…
Industry Peers
Specialty ChemicalsKey Statistics
About Wacker Chemie (ETR: WCH)
›
Wacker Chemie (ETR: WCH) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 15,916 employees.
The shares were at 80.55 EUR on 19 November 2026, up 19.8% over 52 weeks. Its 52-week range is 62.25 EUR to 105.60 EUR: the price is 23.7% below the high and 29.4% above the low.
Its market capitalisation is 4.00B EUR.
Wacker Chemie reports return on equity of -22.8%, an operating margin of 5.1% and revenue up 9.4% year over year.
Its debt exceeds its cash by 260.80M EUR, a debt-to-equity ratio of 0.65. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Hold; their mean price target of 85.91 EUR is 6.7% above the current price. The next earnings report is expected on 10 March 2027.